Generation Bio

Engages in developing genetic medicines through gene therapy platform for intrinsic hepatic diseases and systemic diseases.

Launch date

2016

Employees

Market cap

Enterprise valuation

AUD78m (Public information from Sep 2024)

Cambridge Massachusetts (HQ)

http://generationbio.com

https://twitter.com/generationbio https://www.linkedin.com/company/generationbio

View job openings

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	-	-	-	5.9m	11.5m	6.5m	10.6m
% growth	-	-	-	-	95 %	(44 %)	63 %
EBITDA	(81.1m)	(119m)	(141m)	(133m)	-	-	-
% EBITDA margin	-	-	-	(2258 %)	-	-	-
Profit	(80.5m)	(119m)	(137m)	(127m)	(119m)	(75.6m)	(73.8m)
% profit margin	-	-	-	(2145 %)	(1029 %)	(1163 %)	(698 %)
EV / revenue	-	-	-	-26.3x	-0.7x	27.1x	16.7x
EV / EBITDA	-15.9x	-3.4x	-1.6x	1.2x	-	-	-
R&D budget	58.5m	85.2m	96.7m	93.6m	-	-	-
R&D % of revenue	-	-	-	1586 %	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
Jan 2016	Atlas Venture	$25.0m	Series A
Jan 2018	Atlas Venture	$25.0m	Series A
Feb 2018	Fidelity Investments Invus Casdin Capital Foresite Capital Deerfield Transformation Capital	$100m	Series B
Jan 2020*	Atlas Venture Farallon Capital Management Wellington Management Fidelity Investments Invus Casdin Capital Foresite Capital Deerfield T. Rowe Price	$110m	Series C
Jun 2020	N/A	N/A	IPO
Jan 2021*	N/A	$225m	Post IPO Equity
Mar 2023*	Moderna Therapeutics	$36.0m	Post IPO Equity
Total Funding		AUD402m

Tech stackLearn more about the technologies and tools that this company uses.